Form 4: Lexaria Bioscience Corp. Executive Vanessa Carle Reports Sale of Common Shares

Sentiment:

SEC Form 4


Vanessa Carle, Secretary of Lexaria Bioscience Corp., reports the sale of 2,567 common shares on July 31, 2024.

Summary

  • On July 31, 2024, Vanessa Carle, the Secretary of Lexaria Bioscience Corp., sold 2,567 common shares.
  • The shares were sold at a price of $4 per share.
  • Following the transaction, Carle directly owns 0 common shares.
  • Carle also holds warrants for 67 common shares and various stock options with different exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting a sale of shares by an officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Key Dates

DateDescription
11/13/2019Date of Warrants
04/26/2021Date of Stock Options
06/08/2021Date of Stock Options
09/01/2021Date of Stock Options
08/29/2022Date of Stock Options
05/09/2023Shareholder approval received for repricing stock options
10/26/2023Date of Stock Options
04/26/2024Date of Stock Options
07/31/2024Date of transaction: Sale of 2,567 common shares
08/01/2024Date of signature for the Form 4 filing
11/13/2024Expiration Date of Warrants
04/26/2026Expiration Date of Stock Options
06/08/2026Expiration Date of Stock Options
09/01/2026Expiration Date of Stock Options
08/29/2027Expiration Date of Stock Options
10/26/2028Expiration Date of Stock Options
04/26/2029Expiration Date of Stock Options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.